The Vanishing Refill: Controlled Drug Stock Reconciliation
A community pharmacy in Trinidad dispenses a heavily prescribed controlled analgesic. On Monday the pharmacist counts 480 tablets of the 30 mg strength in the safe and records the count. During the week, 14 prescriptions are filled: nine for 30 tablets, three for 60 tablets, and two for 90 tablets. On Friday the physical count is 232 tablets. The register shows 14 entries but only 13 have a prescriber's signature; one entry was signed by an intern and countersigned by no pharmacist. A staff member says a 60-tablet 'emergency supply' was given to a regular patient whose prescription had expired, with a promise to bring the prescription later. The patient has not returned. The pharmacy's standard operating procedure requires a witnessed count at every shift change and a discrepancy report within 24 hours. The pharmacist-in-charge is on leave and the reliever must decide what to do before closing.
1. Calculate the expected closing balance and quantify the discrepancy. What does the size of the discrepancy suggest about the likely causes?
Read the worked answer
Dispensed total = (9 x 30) + (3 x 60) + (2 x 90) = 270 + 180 + 180 = 630 tablets. Expected balance = 480 - 630 = -150, which is impossible, so the Monday opening count or the recorded quantities must be wrong. If we instead accept the Friday count of 232, the implied dispensed quantity is 480 - 232 = 248 tablets, against 630 tablets recorded. That is a shortfall of 382 tablets in the register relative to the safe, or a physical surplus of 382 relative to the register. The arithmetic mismatch is too large to be a simple miscount of a few tablets; it points to either a transcription error (e.g., 30 recorded as 300, or a whole line entered twice), unrecorded removals, or an opening count that was never verified. The pharmacist should not assume theft: a systematic data-entry or double-counting error is at least as likely, and the discrepancy report should state the possibilities rather than a conclusion.
2. The unsigned entry and the 60-tablet emergency supply without a valid prescription are both regulatory problems. How should the reliever handle each, and in what order of priority?
Read the worked answer
Order of priority: patient safety first, then legal exposure, then documentation. The emergency supply involves a patient who has already received medicine; the immediate question is whether that patient is at risk (dose, duration, interaction) and whether the medicine can be recalled or the patient contacted. The reliever should contact the patient, document the contact, and arrange for a valid prescription or return of unused stock. The supply itself appears to breach the requirement that a controlled drug be dispensed against a valid prescription; an emergency supply of a controlled drug is generally not permitted on the same basis as ordinary medicines, and the pharmacist must record it as an irregularity, not regularise it retrospectively. The unsigned entry is a record-keeping failure: the reliever should not back-sign or have the intern's entry countersigned as if it were compliant, because that falsifies the record. Instead, annotate the entry with the facts (who supplied, when, why no pharmacist signature), notify the pharmacist-in-charge and, where required, the regulatory authority. Both matters go into the discrepancy report within 24 hours, with a factual chronology and copies of the relevant pages.
3. What immediate controls should be put in place before the pharmacy reopens, and what should the follow-up audit cover?
Read the worked answer
Before reopening: perform a full witnessed count of all controlled stocks, not just the one product, and record it as the new baseline signed by two staff. Secure the safe and restrict keys to registered pharmacists. Suspend the emergency-supply practice pending written policy. Separate the roles of dispensing and recording so the person who removes stock is not the only person who records it. For follow-up: audit the last three months of controlled-drug registers against dispensing records and stock counts, review whether any other entries lack a pharmacist signature, check whether the intern was working unsupervised, and verify that shift-change counts were actually performed as the SOP requires (the fact that a 382-tablet gap accumulated suggests they were not). Report findings to the pharmacist-in-charge and the owner, and set a re-audit date. The reliever should also confirm their own legal position: documenting the problem and escalating it is protective; concealing it is not.